The global nuclear receptor ROR-gamma market is expected to grow at a significant CAGR during the forecast period (2022-2028). The RORC (RAR-related orphan receptor C) gene in humans encodes the RAR-related orphan receptor gamma (ROR) protein. ROR is a transcription factor that belongs to the nuclear receptor family. It regulates circadian rhythms and is primarily expressed in immune cells (Th17 cells). It plays a role in the progression of certain cancers. Further, RAR-related orphan nuclear receptor gamma (ROR) has resurfaced as a potential therapeutic for rheumatoid arthritis, autoimmune disorders, multiple sclerosis, psoriasis, psoriatic arthritis, and other diseases. T cells, T helper 17 cells (Th17 cells), and IL-17F have been found to be involved in the pathophysiology of immunological disorders. The IL-23 and IL-17 pathway in humans has been verified by antibodies against IL-17 and IL-23. Several therapeutic candidates have also been found, and proofs of concept have shown that antibodies that suppress the IL-17 family's activity can be utilized to treat the disorders such as rheumatoid arthritis and autoimmune disorders. There are two isoforms of ROR. The lung, liver, kidney, muscle, brown fat, and thymus all express ROR (also known as ROR1).

The rising prevalence of prostate cancer is contributing to the growth of the market. The estimated number of new incidences of prostate cancer in 2020 in the US is approximately 2,281,658 and the mortalities estimated are around 612,390. Globally prostate cancer is the fourth most common cancer in men.  In every 7 men, there is 1 incidence of male prostate cancer. As per Cancer.gov, researchers have discovered a new way to stop the function of a critical molecular driver in androgen-independent or castration-resistant prostate cancer, which is a more advanced form of prostate cancer. The researchers demonstrated that treatment with drug-like small compounds that target a protein called ROR-disrupted the activation of the androgen receptor (AR) in prostate cancer cell lines and in numerous mice models of prostate cancer. The primary mechanism by which prostate cancer cells grow and spread is through AR signaling. Treatment with ROR-inhibitors resulted in significant and long-term tumor shrinkage in mouse models of castration-resistant disease, and the treatment appeared to restore tumor sensitivity to the AR-targeted therapy enzalutamide (Xtandi) in mice with tumors that had previously been resistant to the drug.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period-2022-2028

Segment Covered- 

• By Product 
• By Application 

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Bristol-Myers Squibb Company, and GlaxoSmithKline plc, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
• Global Nuclear Receptor ROR-Gamma Market Report by Segment

By Product 

• VPR-66
• INV-17
• GSK-2981278
• BBI-6000
• Others

By Application

• Hospital
• Clinic
• Others

Global Nuclear Receptor ROR-Gamma Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy

Rest of Europe Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa